IRIS - Res&Arch Institutional Research Information System - Research & Archive

PORCELLATI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.834
EU - Europa 2.851
AS - Asia 2.738
SA - Sud America 440
Continente sconosciuto - Info sul continente non disponibili 238
AF - Africa 60
OC - Oceania 20
Totale 10.181
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.723
SG - Singapore 1.311
IT - Italia 475
CN - Cina 410
IE - Irlanda 389
RU - Federazione Russa 377
SE - Svezia 347
BR - Brasile 343
UA - Ucraina 320
HK - Hong Kong 296
VN - Vietnam 268
DE - Germania 239
FR - Francia 182
FI - Finlandia 155
GB - Regno Unito 114
BD - Bangladesh 95
IN - India 75
ES - Italia 69
KR - Corea 58
CA - Canada 48
AT - Austria 37
TR - Turchia 37
PL - Polonia 36
MX - Messico 33
AR - Argentina 32
ZA - Sudafrica 30
IQ - Iraq 27
JP - Giappone 27
NL - Olanda 25
UZ - Uzbekistan 23
CZ - Repubblica Ceca 19
PK - Pakistan 19
AU - Australia 17
PH - Filippine 14
VE - Venezuela 14
BE - Belgio 13
ID - Indonesia 13
SA - Arabia Saudita 13
CH - Svizzera 12
CO - Colombia 12
EC - Ecuador 12
PE - Perù 9
TT - Trinidad e Tobago 9
RO - Romania 7
AZ - Azerbaigian 6
BO - Bolivia 6
JO - Giordania 6
LT - Lituania 6
MA - Marocco 6
EG - Egitto 5
JM - Giamaica 5
KE - Kenya 5
NP - Nepal 5
DK - Danimarca 4
GR - Grecia 4
IL - Israele 4
MY - Malesia 4
OM - Oman 4
PS - Palestinian Territory 4
PY - Paraguay 4
UY - Uruguay 4
CL - Cile 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EU - Europa 3
LB - Libano 3
RS - Serbia 3
TH - Thailandia 3
TN - Tunisia 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AO - Angola 2
BB - Barbados 2
BW - Botswana 2
EE - Estonia 2
GE - Georgia 2
HU - Ungheria 2
NZ - Nuova Zelanda 2
PA - Panama 2
PT - Portogallo 2
SI - Slovenia 2
XK - ???statistics.table.value.countryCode.XK??? 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
DZ - Algeria 1
ET - Etiopia 1
FJ - Figi 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
IM - Isola di Man 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
Totale 9.936
Salva come PNG Salva come JPEG
Città #
Singapore 953
Chandler 474
San Jose 425
Dublin 389
Hong Kong 293
Ashburn 241
San Mateo 224
Boardman 177
Jacksonville 160
Santa Clara 145
Moscow 129
Altamura 112
Medford 110
Princeton 109
Beijing 103
Lauterbourg 103
Munich 93
Wilmington 92
Perugia 91
Lawrence 80
Ann Arbor 79
New York 79
Dong Ket 76
Los Angeles 67
Seoul 58
Andover 53
Ho Chi Minh City 53
Helsinki 52
Valencia 50
Rome 45
The Dalles 42
Des Moines 39
Hanoi 37
Frankfurt am Main 33
São Paulo 28
Saint Petersburg 27
Brooklyn 26
Chicago 25
Piscataway 25
Woodbridge 23
Warsaw 22
Norwalk 21
Nuremberg 21
Falls Church 20
Milan 20
Tokyo 20
Turku 20
Orem 19
Amsterdam 16
Tashkent 16
Toronto 16
Vienna 16
Amelia 15
Brno 14
Izmir 13
London 13
Atlanta 12
Baghdad 12
Brussels 12
Da Nang 12
Denver 12
Falkenstein 12
San Francisco 12
Stockholm 12
Dallas 11
Montreal 11
Mumbai 11
Houston 10
Phoenix 10
Shanghai 10
Ankara 9
Boston 9
Foligno 9
Johannesburg 9
Mexico City 9
Poplar 9
Porto Alegre 9
Belo Horizonte 8
Bexley 8
Buffalo 8
Dhaka 8
Istanbul 8
San Paolo di Civitate 8
Auburn Hills 7
Council Bluffs 7
Guayaquil 7
Hải Dương 7
Melbourne 7
Redmond 7
Columbus 6
Curitiba 6
Durban 6
Florence 6
Fremont 6
Goiânia 6
Guangzhou 6
Haiphong 6
Hyderabad 6
Juárez 6
Rio de Janeiro 6
Totale 6.080
Salva come PNG Salva come JPEG
Nome #
Ipoglicemia da iperinsulinismo organico: un caso di nesidioblastosi dell’adulto. 215
Adrenaline vs glucagon in the primacy of glucose counterregulation 175
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 158
Hypoglycemia 155
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 154
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 150
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 135
Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study 130
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 128
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 128
A novel surrogate index for hepatic insulin resistance. 126
EFFECT OF PYRIDOXAL 5'-PHOSPHATE AND VALPROICACID ON PHOSPHOLIPID SYNTHESIS INNEUROBLASTOMA NA 125
Administration of Neutral Protamine Hagedorn insulin at bedtime versus dinner in Type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control: a randomized, controlled trial. 125
Awareness, identification and prevention of insulin injection-associated lipodystrophies 121
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 120
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 120
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 120
Cognitive function in hypoglycaemia 117
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 116
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 115
Ipoglicemia: implicazioni cliniche e impatto sulla salute 115
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 113
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 112
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 112
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 110
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 108
[Usefulness of plantar pressure measurement for the prevention and treatment of neuropathic diabetic foot]. 107
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 105
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 103
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 103
Alternate splicing in human Na+-MI cotransporter gene yelds differentially regulated trasport isoforms 101
Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. 101
EPIDEMIOLOGICAL SURVEY FOR THE DETECTION OF NON–TRAUMATIC LOWER EXTREMITY AMPUTATIONS IN DIABETIC PATIENTS IN THE UMBRIA REGION (ITALY). 101
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 99
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin 99
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 97
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 97
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. 96
Body composition and common carotid artery remodeling in a healthy population 96
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 95
Glucagon: the effects of its excess and deficiency on insulin action 94
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 94
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 93
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 93
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 93
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 93
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 91
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 89
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 88
ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role? 87
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 87
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 85
Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. 85
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 84
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 84
One hour post-load plasma glucose and 3 year risk of worsening fasting and 2 hour glucose tolerance in the RISC cohort 83
The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study 82
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 82
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 82
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 82
Obesity and carotid artery remodeling 81
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 79
Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure 79
Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage 76
Effect of sedentary behaviour and vigorous physical activity on segment-specific carotid wall thickness and its progression in a healthy population 75
Responses to hypoglycemia in diabetic autonomic neuropathy. 75
Insulin therapy and hypoglycemia: the size of the problem 74
Quando “i conti non tornano” (Caso clinico) G It Diabetol Metab 26:172-175 73
Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. 73
Low levels of unmodified insulin glargine in plasma of people with type 2 diabetes requiring high doses of basal insulin 73
Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. 72
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. 71
The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women 71
Recovery and prevention of hypoglycaemia unawareness in Type 1 diabetes mellitus 71
Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study. Response to Banarer. 70
Modification and validation of the triglyceride-to-HDL cholesterol ratio as a surrogate of insulin sensitivity in white juveniles and adults without diabetes mellitus: The single point insulin sensitivity estimator (SPISE) 70
Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk 68
Mechanisms of arterial hypotension after therapeutic dose of subcutaneous insulin in diabetic autonomic neuropathy. 67
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 66
Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes. 66
Glucagon as a therapeutic approach to severe hypoglycemia: After 100 years, is it still the antidote of insulin? 66
Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. 64
How to accurately establish pharmacokinetics/ pharmacodynamics of long- Acting insulins in humans: Relevance to biosimilar insulins 64
Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology 64
INSULIN SENSITIVITY IN TYPE 2 DIABETIC PATIENTS IS DIFFERENT BETWEEN GLUCOSE AND PROTEIN METABOLISM 63
Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial 62
The physiological basis of insulin therapy in people with diabetes mellitus 62
Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways 62
Impact of family history on relations between insulin resistance, LDL cholesterol and carotid IMT in healthy adults 61
L’insulina biosimilare è “clinicamente uguale” all’originator, ma… 60
Shape of the OGTT glucose curve and risk of impaired glucose metabolism in the EGIR-RISC cohort 60
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes mellitus. 59
Gli Analoghi dell’Insulina ad Azione Ritardo: dalla storia di ieri alle opzioni di oggi 59
Metabolic effects of an SGLT2 inhibitor (Dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes. Diabetes care 2020;43:2128– 2136 59
The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime? 57
Real-time continuous glucose monitoring decreases the risk of severe hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia 57
Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials 57
Pharmacokinetics and pharmacodynamics of basal insulins. 56
Ipoglicemia: Implicazioni cliniche e impatto sulla salute 56
Renal function markers and insulin sensitivity after 3 years in a healthy cohort, the EGIR-RISC study 54
Totale 9.206
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.318
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.318
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022819 0 156 21 59 20 14 8 271 17 25 102 126
2022/20231.510 116 287 17 126 115 191 2 69 527 6 43 11
2023/2024658 36 76 35 11 5 7 121 2 44 28 147 146
2024/20251.624 25 157 45 98 264 37 61 146 319 108 214 150
2025/20263.761 262 228 187 359 506 267 691 215 519 300 123 104
2026/2027227 129 98 0 0 0 0 0 0 0 0 0 0
Totale 10.181